BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 20803239)

  • 1. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
    Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
    Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Pyrazolo[3,4-
    Neuber C; Tröster A; Löser R; Belter B; Schwalbe H; Pietzsch J
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33153234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EphB4 forward signalling mediates angiogenesis caused by CCM3/PDCD10-ablation.
    You C; Zhao K; Dammann P; Keyvani K; Kreitschmann-Andermahr I; Sure U; Zhu Y
    J Cell Mol Med; 2017 Sep; 21(9):1848-1858. PubMed ID: 28371279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells.
    Füller T; Korff T; Kilian A; Dandekar G; Augustin HG
    J Cell Sci; 2003 Jun; 116(Pt 12):2461-70. PubMed ID: 12734395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EphrinB2/EphB4 signaling regulates non-sprouting angiogenesis by VEGF.
    Groppa E; Brkic S; Uccelli A; Wirth G; Korpisalo-Pirinen P; Filippova M; Dasen B; Sacchi V; Muraro MG; Trani M; Reginato S; Gianni-Barrera R; Ylä-Herttuala S; Banfi A
    EMBO Rep; 2018 May; 19(5):. PubMed ID: 29643120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.
    Bai J; Wang YJ; Liu L; Zhao YL
    J Int Med Res; 2014 Apr; 42(2):405-15. PubMed ID: 24517927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The critical role of the interplays of EphrinB2/EphB4 and VEGF in the induction of angiogenesis.
    Du E; Li X; He S; Li X; He S
    Mol Biol Rep; 2020 Jun; 47(6):4681-4690. PubMed ID: 32488576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
    Kertesz N; Krasnoperov V; Reddy R; Leshanski L; Kumar SR; Zozulya S; Gill PS
    Blood; 2006 Mar; 107(6):2330-8. PubMed ID: 16322467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
    Tröster A; Heinzlmeir S; Berger BT; Gande SL; Saxena K; Sreeramulu S; Linhard V; Nasiri AH; Bolte M; Müller S; Kuster B; Médard G; Kudlinzki D; Schwalbe H
    ChemMedChem; 2018 Aug; 13(16):1629-1633. PubMed ID: 29928781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
    Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
    Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
    Chen Y; Zhang H; Zhang Y
    Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EphB4/ TNFR2/ERK/MAPK signaling pathway comprises a signaling axis to mediate the positive effect of TNF-α on osteogenic differentiation.
    Zhang Y; Yang C; Ge S; Wang L; Zhang J; Yang P
    BMC Mol Cell Biol; 2020 Apr; 21(1):29. PubMed ID: 32299362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
    Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
    Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
    Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment.
    Das A; Shergill U; Thakur L; Sinha S; Urrutia R; Mukhopadhyay D; Shah VH
    Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G908-15. PubMed ID: 20338920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development.
    Cowan CA; Yokoyama N; Saxena A; Chumley MJ; Silvany RE; Baker LA; Srivastava D; Henkemeyer M
    Dev Biol; 2004 Jul; 271(2):263-71. PubMed ID: 15223333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.
    Djokovic D; Trindade A; Gigante J; Badenes M; Silva L; Liu R; Li X; Gong M; Krasnoperov V; Gill PS; Duarte A
    BMC Cancer; 2010 Nov; 10():641. PubMed ID: 21092311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration.
    Sturz A; Bader B; Thierauch KH; Glienke J
    Biochem Biophys Res Commun; 2004 Jan; 313(1):80-8. PubMed ID: 14672701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor-A inhibits EphB4 and stimulates delta-like ligand 4 expression in adult endothelial cells.
    Yang C; Guo Y; Jadlowiec CC; Li X; Lv W; Model LS; Collins MJ; Kondo Y; Muto A; Shu C; Dardik A
    J Surg Res; 2013 Jul; 183(1):478-86. PubMed ID: 23394931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EphrinB2/EphB4 Signaling Regulates DPSCs to Induce Sprouting Angiogenesis of Endothelial Cells.
    Gong T; Xu J; Heng B; Qiu S; Yi B; Han Y; Lo ECM; Zhang C
    J Dent Res; 2019 Jul; 98(7):803-812. PubMed ID: 31017515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.